Cholesterol emboli syndrome laboratory findings: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
Line 4: Line 4:
==Overview==
==Overview==
== Laboratory Findings ==  
== Laboratory Findings ==  
===Blood and urine===
Tests for [[inflammation]] ([[C-reactive protein]] and the [[erythrocyte sedimentation rate]]) are typically elevated, and abnormal [[liver enzyme]]s may be seen. If the kidneys are involved, tests of [[renal function]] (such as [[urea]] and [[creatinine]]) are elevated. The [[complete blood count]] may show particularly high numbers of a type of [[white blood cell]] known as ''[[eosinophil]]s'' (more than 0.5 billion per liter); this occurs in only 60-80% of cases, so normal eosinophil counts do not rule out the diagnosis. Examination of the urine may show [[red blood cell]]s (occasionally in [[urinary casts|casts]] as seen under the microscope) and increased levels of protein; in a third of the cases with kidney involvement, eosinophils can also be detected in the urine. If vasculitis is suspected, [[complement]] levels may be determined as reduced levels are often encountered in vasculitis; complement is a group of proteins that forms part of the innate [[immune system]]. Complement levels are frequently reduced in cholesterol embolism, limiting the use of this test in the distinction between vasculitis and cholesterol embolism.<ref>{{cite journal |author=Cosio FG, Zager RA, Sharma HM |title=Atheroembolic renal disease causes hypocomplementaemia |journal=Lancet |volume=2 |issue=8447 |pages=118–21 |year=1985 |month=July |pmid=2862317 |doi=10.1016/S0140-6736(85)90225-9}}</ref>


* Organ specific damage
*Laboratory findings consistent with the diagnosis of [[Cholesterol emboli syndrome]] include<ref name="Ozkok2019">{{cite journal|last1=Ozkok|first1=Abdullah|title=<p>Cholesterol-embolization syndrome: current perspectives</p>|journal=Vascular Health and Risk Management|volume=Volume 15|year=2019|pages=209–220|issn=1178-2048|doi=10.2147/VHRM.S175150}}</ref><ref name="FukumotoTsutsui2003">{{cite journal|last1=Fukumoto|first1=Yoshihiro|last2=Tsutsui|first2=Hiroyuki|last3=Tsuchihashi|first3=Miyuki|last4=Masumoto|first4=Akihiro|last5=Takeshita|first5=Akira|title=The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study|journal=Journal of the American College of Cardiology|volume=42|issue=2|year=2003|pages=211–216|issn=07351097|doi=10.1016/S0735-1097(03)00579-5}}</ref>
*:* Renal failure - rapidly progressive in many cases <cite>greenberg</cite>
**Tests for [[inflammation]] ([[C-reactive protein]] and the [[erythrocyte sedimentation rate]]) are typically elevated
*:* Myocardial infarction - serum creatine kinase (CPK) and troponin elevation
**abnormal [[liver enzyme]]s
*:* Mesenteric ischemia - Bloody (OB+) stool common
**If the kidneys are involved, tests of [[renal function]] (such as [[urea]] and [[creatinine]]) are elevated.
*:* Stroke
**The [[complete blood count]] may show particularly high numbers of a type of [[white blood cell]] known as ''[[eosinophil]]s'' (more than 0.5 billion per liter); this occurs in only 60-80% of cases, so normal [[eosinophil]] counts do not rule out the diagnosis.<ref name="CecioniFassio2007">{{cite journal|last1=Cecioni|first1=Ilaria|last2=Fassio|first2=Filippo|last3=Gori|first3=Stefano|last4=Giudizi|first4=Maria Grazia|last5=Romagnani|first5=Sergio|last6=Almerigogna|first6=Fabio|title=Eosinophilia in cholesterol atheroembolic disease|journal=Journal of Allergy and Clinical Immunology|volume=120|issue=6|year=2007|pages=1470–1471|issn=00916749|doi=10.1016/j.jaci.2007.07.014}}</ref>
* Full septic picture may ensue
**Examination of the urine may show [[red blood cell]]s (occasionally in [[urinary casts|casts]] as seen under the microscope) and increased levels of [[protein]]; in a third of the cases with [[kidney]] involvement, [[eosinophils]] can also be detected in the [[urine]].
*:* Adult Respiratory Distress Syndrome (ARDS) <cite>greenberg</cite>  
**If [[vasculitis]] is suspected, [[complement]] levels may be determined as reduced levels are often encountered in [[vasculitis]][[; complement]] is a group of [[proteins]] that forms part of the innate [[immune system]]. [[Complement]] levels are frequently reduced in [[cholesterol embolism syndrome]], limiting the use of this test in the distinction between [[vasculitis]] and [[cholesterol embolism syndrome]].<ref>{{cite journal |author=Cosio FG, Zager RA, Sharma HM |title=Atheroembolic renal disease causes hypocomplementaemia |journal=Lancet |volume=2 |issue=8447 |pages=118–21 |year=1985 |month=July |pmid=2862317 |doi=10.1016/S0140-6736(85)90225-9}}</ref>
*:* Microangiopathic hemolysis (disseminated intravascular coagulopathy)  
*:* Hypotension is usually a late finding


=== Electrolyte and Biomarker Studies ===
* If Organ damage occurs, laboratory findings include
*:* [[Renal failure]] - increased serum [[creatinine]] and BUN <cite>greenberg</cite>
*:* [[Myocardial infarction]] - serum [[creatine kinase]] (CPK) and [[troponin]] elevation
*:* [[Mesenteric ischemia]] - Bloody (OB+) stool common


* Peripheral eosinophilia <cite>moolenaarneth</cite>  
=== Biomarker Studies ===
* Urinary eosinophilia - usually in patients with cholesterol-renal disease  
*increased ESR and CRP
* May have leukocytosis (even >20K/µL) with left shift  
* Peripheral [[eosinophilia]] <cite>moolenaarneth</cite>  
* Hypocomplementemia is common
* [[eosinophiluria]] - usually in patients with cholesterol-renal disease  
* Sed rates are nonspecifically elevated
* [[Hematuria]]
* Thrombocytopenia due to aggregation and complement activation
* [[proteinuria]]
* May have [[leukocytosis]] (even >20K/µL) with left shift  
* [[Hypocomplementemia]] is common
* [[Thrombocytopenia]] due to aggregation and complement activation


==References==
==References==

Latest revision as of 22:15, 19 February 2021

Cholesterol emboli syndrome Microchapters

Home

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Cholesterol emboli syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cholesterol emboli syndrome laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cholesterol emboli syndrome laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cholesterol emboli syndrome laboratory findings

CDC on Cholesterol emboli syndrome laboratory findings

Cholesterol emboli syndrome laboratory findings in the news

Blogs on Cholesterol emboli syndrome laboratory findings

Directions to Hospitals Treating Cholesterol emboli syndrome

Risk calculators and risk factors for Cholesterol emboli syndrome laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Laboratory Findings

Biomarker Studies

References

  1. Ozkok, Abdullah (2019). "

    Cholesterol-embolization syndrome: current perspectives

    ". Vascular Health and Risk Management. Volume 15: 209–220. doi:10.2147/VHRM.S175150. ISSN 1178-2048.
  2. Fukumoto, Yoshihiro; Tsutsui, Hiroyuki; Tsuchihashi, Miyuki; Masumoto, Akihiro; Takeshita, Akira (2003). "The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study". Journal of the American College of Cardiology. 42 (2): 211–216. doi:10.1016/S0735-1097(03)00579-5. ISSN 0735-1097.
  3. Cecioni, Ilaria; Fassio, Filippo; Gori, Stefano; Giudizi, Maria Grazia; Romagnani, Sergio; Almerigogna, Fabio (2007). "Eosinophilia in cholesterol atheroembolic disease". Journal of Allergy and Clinical Immunology. 120 (6): 1470–1471. doi:10.1016/j.jaci.2007.07.014. ISSN 0091-6749.
  4. Cosio FG, Zager RA, Sharma HM (1985). "Atheroembolic renal disease causes hypocomplementaemia". Lancet. 2 (8447): 118–21. doi:10.1016/S0140-6736(85)90225-9. PMID 2862317. Unknown parameter |month= ignored (help)


Template:WikiDoc Sources